Coffee consumption delays the hepatitis and suppresses the inflammation related gene expression in the Long-Evans Cinnamon rat

Clinical Nutrition

Volumn 33, Issue 2, 2014, Pages 302-310

  Katayama, Masafumi ^a   Donai, Kenichiro ^a   Sakakibara, Hiroyuki ^b   Ohtomo, Yukiko ^a   Miyagawa, Makoto ^c   Kuroda, Kengo ^a   Kodama, Hiroko ^d   Suzuki, Kazufumi ^e   Kasai, Noriyuki ^f   Nishimori, Katsuhiko ^a   Uchida, Takafumi ^a   Watanabe, Kouichi ^a   Aso, Hisashi ^a   Isogai, Emiko ^a   Sone, Hideko ^g   Fukuda, Tomokazu ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TEIKYO HEISEI UNIVERSITY   (Japan)

^e Institute for Animal Reproduction   (Japan)

^f TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES   (Japan)

Author keywords

Coffee; Cytokine; Experimental animal model; Hepatitis; Liver cancer; Pre neoplastic foci

Indexed keywords

ALANINE AMINOTRANSFERASE; COPPER; CYTOKINE; GLUTATHIONE TRANSFERASE; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATP7B GENE; CANCER INCIDENCE; COFFEE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE SEVERITY; DRINKING BEHAVIOR; GENE; GENE EXPRESSION; GENE MUTATION; HEPATITIS; INFLAMMATORY RELATED GENE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER LEVEL; LONG EVANS CINNAMON RAT; MALE; METAL METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRECANCER; PROTEIN EXPRESSION; RAT; SURVIVAL RATE;

COFFEE; CYTOKINE; EXPERIMENTAL ANIMAL MODEL; HEPATITIS; LIVER CANCER; PRE-NEOPLASTIC FOCI;

ADENOSINE TRIPHOSPHATASES; ALANINE TRANSAMINASE; ANIMALS; CAFFEINE; CATION TRANSPORT PROTEINS; CINNAMATES; COFFEE; COPPER; GENE EXPRESSION; GLUTATHIONE TRANSFERASE; HEPATITIS; INFLAMMATION; INTERLEUKIN-6; IRON; LIVER; LIVER NEOPLASMS; MALE; OXIDATIVE STRESS; RATS; RATS, INBRED LEC; RNA, MESSENGER; SMAD2 PROTEIN; SMAD3 PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895431554     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2013.05.006     Document Type: Article

References (45)

1. Freedman N.D., Park Y., Abnet C.C., Hollenbeck A.R., Sinha R. Association of coffee drinking with total and cause-specific mortality. New Engl J Med 2012, 366:1891-1904.
2. Klatsky A.L., Armstrong M.A. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992, 136:1248-1257.
3. Larsson S.C., Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007, 132:1740-1745.
4. Ruhl C.E., Everhart J.E. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005, 128:24-32.
5. Shimazu T., Tsubono Y., Kuriyama S., Ohmori K., Koizumi Y., Nishino Y., et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005, 116:150-154.
6. Kurozawa Y., Ogimoto I., Shibata A., Nose T., Yoshimura T., Suzuki H., et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005, 93:607-610.
7. Shin J.W., Wang J.H., Kang J.K., Son C.G. Experimental evidence for the protective effects of coffee against liver fibrosis in SD rats. J Sci Food Agric 2010, 90:450-455.
8. Furtado K.S., Prado M.G., Aguiar E.S.M.A., Dias M.C., Rivelli D.P., Rodrigues M.A., et al. Coffee and caffeine protect against liver injury induced by thioacetamide in male Wistar rats. Basic Clin Pharmacol Toxicol 2012, 111:339-347.
9. Ruhl C.E., Everhart J.E. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005, 129:1928-1936.
10. Gressner O.A. About coffee, cappuccino and connective tissue growth factor-Or how to protect your liver!?. Environ Toxicol Pharmacol 2009, 28:1-10.
11. Gressner O.A. Less Smad2 is good for you! A scientific update on coffee's liver benefits. Hepatology 2009, 50:970-978.
12. Gressner O.A. Chapter 4-Intracrine signaling mechanisms of activin a and TGF-beta 2011, 59-77. Elsevier Inc.
13. Gressner O.A., Lahme B., Siluschek M., Rehbein K., Weiskirchen R., Gressner A.M. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor β actions in hepatocytes-But without modulating bone morphogenetic protein 7 signaling. Hepatology 2009, 49:2021-2030.
14. Fukuda T., Scott G., Komatsu Y., Araya R., Kawano M., Ray M.K., et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis 2006, 44:159-167.
15. Shi X., Dalal N.S., Jain A.C. Antioxidant behaviour of caffeine: efficient scavenging of hydroxyl radicals. Food Chem Toxicol 1991, 29:1-6.
16. Panchal S.K., Poudyal H., Waanders J., Brown L. Coffee extract attenuates changes in cardiovascular and hepatic structure and function without decreasing obesity in high-carbohydrate, high-fat diet-fed male rats. J Nutr 2012, 142:690-697.
17. Takeichi N. Hepatocarcinogenesis in the LEC rat with hereditary hepatitis. Princess Takamatsu Symp 1991, 22:361-370.
18. Marquez A., Villa-Trevino S., Gueraud F. The LEC rat: a useful model for studying liver carcinogenesis related to oxidative stress and inflammation. Redox Rep 2007, 12:35-39.
19. Yoshida M.C., Masuda R., Sasaki M., Takeichi N., Kobayashi H., Dempo K., et al. New mutation causing hereditary hepatitis in the laboratory rat. J Hered 1987, 78:361-365.
20. Sugiyama T., Takeichi N., Kobayashi H., Yoshida M.C., Sasaki M., Taniguchi N. Metabolic predisposition of a novel mutant (LEC rats) to hereditary hepatitis and hepatoma: alterations of the drug metabolizing enzymes. Carcinogenesis 1988, 9:1569-1572.
21. Wu J., Forbes J.R., Chen H.S., Cox D.W. The LEC rat has a deletion in the copper transporting ATPase gene homologous to the Wilson disease gene. Nat Genet 1994, 7:541-545.
22. Sone H., Maeda M., Wakabayashi K., Takeichi N., Mori M., Sugimura T., et al. Inhibition of hereditary hepatitis and liver tumor development in Long-Evans Cinnamon rats by the copper-chelating agent trientine dihydrochloride. Hepatology 1996, 23:764-770.
23. Sone H., Li Y.J., Ishizuka M., Aoki Y., Nagao M. Increased mutant frequency and altered mutation spectrum of the lacI transgene in Wilson disease rats with hepatitis. Cancer Res 2000, 60:5080-5086.
24. Jia G., Takahashi R., Zhang Z., Tsuji Y., Sone H. Aldo-keto reductase 1 family B7 is the gene induced in response to oxidative stress in the livers of Long-Evans Cinnamon rats. Int J Oncol 2006, 29:829-838.
25. Sakakibara H., Honda Y., Nakagawa S., Ashida H., Kanazawa K. Simultaneous determination of all polyphenols in vegetables, fruits, and teas. J Agric Food Chem 2003, 51:571-581.
26. Kilkenny C., Browne W.J., Cuthill I.C., Emerson M. Altman DG Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8:e1000412.
27. Fukuda T., Kondo Y., Nakagama H. The anti-proliferative effects of the CHFR depend on the forkhead associated domain, but not E3 ligase activity mediated by ring finger domain. PLoS One 2008, 3:e1776.
28. Sone H., Wakabayashi K., Kushida H., Sugimura T., Nagao M. Induction of preneoplastic lesions by a low dose of 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) in the livers of rats treated with carbon tetrachloride. Carcinogenesis 1992, 13:793-797.
29. Ito N., Hasegawa R., Shirai T., Fukushima S., Hakoi K., Takaba K., et al. Enhancement of GST-P positive liver cell foci development by combined treatment of rats with five heterocyclic amines at low doses. Carcinogenesis 1991, 12:767-772.
30. Suzuki S., Asamoto M., Tsujimura K., Shirai T. Specific differences in gene expression profile revealed by cDNA microarray analysis of glutathione S-transferase placental form (GST-P) immunohistochemically positive rat liver foci and surrounding tissue. Carcinogenesis 2004, 25:439-443.
31. Higashi K., Hiai H., Higashi T., Muramatsu M. Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle. Cancer Lett 2004, 209:155-163.
32. Freedman N.D., Everhart J.E., Lindsay K.L., Ghany M.G., Curto T.M., Shiffman M.L., et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology 2009, 50:1360-1369.
33. Torres D.M., Harrison S.A. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology 2013, 144:670-672.
34. Fujise Y., Okano J., Nagahara T., Abe R., Imamoto R., Murawaki Y. Preventive effect of caffeine and curcumin on hepato-carcinogenesis in diethylnitrosamine-induced rats. Int J Oncol 2012, 40:1779-1788.
35. Fong R.N., Gonzalez B.P., Fuentealba I.C., Cherian M.G. Role of tumor necrosis factor-alpha in the development of spontaneous hepatic toxicity in Long-Evans Cinnamon rats. Toxicol Appl Pharmacol 2004, 200:121-130.
36. Gressner O.A. In the Search of the magic bullet. ... YGAST 2010, 139:1453-1457.
37. Gressner O.A., Lahme B., Rehbein K., Siluschek M., Weiskirchen R., Gressner A.M. Pharmacological application of caffeine inhibits TGF-β-stimulated connective tissue growth factor expression in hepatocytes via PPARγ and SMAD2/3-dependent pathways. J Hepatol 2008, 49:758-767.
38. Gressner O.A., Siluschek M., Lahme B., Gressner A.M. Intraperitoneal application of caffeine prevents d-galactosamine-induced hepatic expression of connective tissue growth factor (CTGF/CCN2) in the rat. J Hepatol 2009, 50:1053-1055.
39. Gressner O.A., Gressner A.M. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008, 28:1065-1079.
40. Wang Y., Ho C.T. Polyphenolic chemistry of tea and coffee: a century of progress. J Agric Food Chem 2009, 57:8109-8114.
41. Wu M.D., Cheng M.J., Wang W.Y., Huang H.C., Yuan G.F., Chen J.J., et al. Antioxidant activities of extracts and metabolites isolated from the fungus Antrodia cinnamomea. Nat Prod Res 2011, 25:1488-1496.
42. Vitaglione P., Morisco F., Mazzone G., Amoruso D.C., Ribecco M.T., Romano A., et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010, 52:1652-1661.
43. Takahashi M., Mutoh M., Shoji Y., Sato H., Kamanaka Y., Naka M., et al. Suppressive effect of an inducible nitric oxide inhibitor, ONO-1714, on AOM-induced rat colon carcinogenesis. Nitric Oxide 2006, 14:130-136.
44. Carraway R.E., Cochrane D.E. Enhanced vascular permeability is hypothesized to promote inflammation-induced carcinogenesis and tumor development via extravasation of large molecular proteins into the tissue. Med Hypotheses 2012, 78:738-743.
45. Wu J., Akaike T., Hayashida K., Okamoto T., Okuyama A., Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res Gann 2001, 92:439-451.